H Mohammed, DD Pham-Tran, ZYM Yeoh, B Wang… - Vaccines, 2023 - mdpi.com
Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B. 1.1. 529) is limited. This systematic review aimed to investigate the real-world effectiveness …
A Rössler, A Netzl, L Knabl, H Schäfer, SH Wilks… - Nature …, 2022 - nature.com
Several studies have shown that SARS-CoV-2 BA. 1 omicron is an immune escape variant. Meanwhile, however, omicron BA. 2 and BA. 5 became dominant in many countries and …
Background More than two years into the COVID-19 pandemic, most of the population has developed anti-SARS-CoV-2 antibodies from infection and/or vaccination. However, public …
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 prompted scientific, medical, and biotech communities to investigate infection-and vaccine …
R Wang, H Huang, C Yu, C Sun, J Ma, D Kong… - Science China Life …, 2023 - Springer
Multivalent vaccines combining crucial mutations from phylogenetically divergent variants could be an effective approach to defend against existing and future SARS-CoV-2 variants …
G Kenny, S O'Reilly, N Wrigley Kelly, R Negi… - Nature …, 2023 - nature.com
SARS-CoV-2 neutralising antibodies provide protection against COVID-19. Evidence from early vaccine trials suggested binding antibody thresholds could serve as surrogate markers …
B Mühlemann, SH Wilks, L Baracco, M Bekliz… - Science Translational …, 2024 - science.org
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires ongoing monitoring to judge the ability of newly arising variants to escape the immune …
J Fröberg, VJCH Koomen… - The Journal of …, 2024 - academic.oup.com
Background Mucosal antibodies play a critical role in preventing SARS-CoV-2 infections or reinfections by blocking the interaction of the receptor-binding domain (RBD) with the …